Dynamic Technology Lab Private Ltd Buys 2,434 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Dynamic Technology Lab Private Ltd increased its holdings in Charles River Laboratories International by 47.3% during the first quarter, owning 7,584 shares valued at approximately $1.14 million.
• Several large investors, including Ameriprise Financial Inc and Jefferies Financial Group Inc, also boosted their stakes in Charles River Laboratories in the fourth quarter, highlighting significant institutional interest.
• Analysts have varying ratings for the stock, with some upgrades leading to a consensus price target of $175.69 and a reported earnings per share of $3.12, surpassing expectations.

Dynamic Technology Lab Private Ltd lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 47.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,584 shares of the medical research company's stock after buying an additional 2,434 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Charles River Laboratories International were worth $1,142,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Gotham Asset Management LLC increased its holdings in shares of Charles River Laboratories International by 25.1% in the first quarter. Gotham Asset Management LLC now owns 154,777 shares of the medical research company's stock worth $23,297,000 after buying an additional 31,087 shares during the period. Ariel Investments LLC grew its stake in shares of Charles River Laboratories International by 3.1% in the first quarter. Ariel Investments LLC now owns 1,100,776 shares of the medical research company's stock worth $165,689,000 after purchasing an additional 33,449 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Charles River Laboratories International by 304.7% in the first quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company's stock worth $94,484,000 after purchasing an additional 472,606 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in shares of Charles River Laboratories International by 3,090.9% in the first quarter. Canada Pension Plan Investment Board now owns 105,300 shares of the medical research company's stock worth $15,850,000 after purchasing an additional 102,000 shares during the last quarter. Finally, State of Wyoming grew its stake in shares of Charles River Laboratories International by 16.5% in the first quarter. State of Wyoming now owns 1,468 shares of the medical research company's stock worth $221,000 after purchasing an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 4.1%

Charles River Laboratories International stock traded down $6.51 during trading hours on Friday, hitting $153.23. 768,762 shares of the stock traded hands, compared to its average volume of 734,361. The firm's 50-day moving average price is $160.79 and its two-hundred day moving average price is $148.72. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market cap of $7.54 billion, a PE ratio of -115.21, a PEG ratio of 5.11 and a beta of 1.47. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.80 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares of the company's stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on CRL. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their target price for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. JPMorgan Chase & Co. raised their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Barclays raised their target price on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. Jefferies Financial Group raised Charles River Laboratories International from a "hold" rating to a "buy" rating and raised their target price for the stock from $142.00 to $195.00 in a research note on Tuesday. Finally, Wall Street Zen raised Charles River Laboratories International from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Six research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $177.07.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).